1 / 15

Vasodilating Versus First-Generation β-blockers for Cardiovascular Protection

Vasodilating Versus First-Generation β-blockers for Cardiovascular Protection. Scott Morgan MSIII November 2012. Introduction. Hypertension (HTN) Defined as BP >140/90 mmHg Prevalence in US adults is 29% or approximately 59 million Risk factor for several diseases: Cardiovascular (CV)

erik
Download Presentation

Vasodilating Versus First-Generation β-blockers for Cardiovascular Protection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vasodilating Versus First-Generation β-blockers for Cardiovascular Protection Scott Morgan MSIII November 2012

  2. Introduction • Hypertension (HTN) • Defined as BP >140/90 mmHg • Prevalence in US adults is 29% or approximately 59 million • Risk factor for several diseases: • Cardiovascular (CV) • Cerebrovascular • Renovascular • β-blockers • Discovered in mid 1960s • Were first-line HTN treatment previously • Currently falling out of favor due to side effects

  3. β-blocker Classes

  4. Vasodilating Effects • First and Second-Generation (older generation) • No vasodilation • Third-Generation • Nonselective w/ Vasodilation • Block vascular α-receptors • Carvedilol, bucindolol, labetalol • β1-selective w/ Vasodilation • Increase NO • Nebivolol

  5. 1st Generation Pharmacology • Inhibits catecholamines acting on β1-receptors in heart • Decreases HR and contractility • Leads to decrease CO (SV x HR) and BP • Decreases cardiac work and oxygen demand • Inhibits β1-receptors on juxtaglomerular apparatus in kidneys • Decreases renin release • Leads to decreased activation of renin angiotensin aldosterone system (RAAS) • Inhibits presynaptic transmission in CNS • Decreases catecholamine release

  6. Older Gen Clinical Indications • Coronary heart disease • Heart failure • Reduce mortality by 30% in HF w/o preserved ejection fraction • Post-myocardial infarction • Prevent catecholamine arrhythmogenic effects such as ventricular tachyarrhymias • Chronic stable angina • Reduction in cardiovascular events • PTs with • advanced age • LV dysfunction • Anterior MI

  7. Older Gen for Blood Pressure • Deceased CO • Rebound peripheral vasoconstriction to maintain BP • Leads to chronic HTN • Decreased skeletal muscle perfusion • Adverse effects on lipid and glucose metabolism • Less effective in elderly and black populations • Tend to have low plasma renin HTN • Diuretics are more effective • Contraindicated in asthmatics • β2 effects cause bronchoconstriction • Failed to show reduction in myocardium remodeling • LVH still occurs similarly to uncontrolled HTN

  8. Compliance Issues • Lethargy • Drowsiness • Depression • Peripheral vascular effects • Cold extremities • Sexual side effects • Erectile dysfunction • Orgasmic dysfunction • Can worsen • Diabetes mellitus • Decreased insulin release by block β2 receptors in pancreas • COPD • PVD

  9. Nonselective 3rd Gen β-blockers • Carvedilol, bucindolol, metoprolol • Block vascular α-receptors • Decreased PVR and increased glucose delivery to muscles • Increases insulin sensitivity • Normally vasodilates by NO, but vasoconstricts by SNS • Diabetes and HTN blunt NO effects allowing SNS to increase PVR • Can raise HDL and lower LDL levels • Increases renal blood flow • Less activation of RAAS • Reduces microalbuminuria • No negative BUN/creatinine effects

  10. Carvedilol • Better tolerated in elderly • Body already has β-blocker like effects • Decreased β-adrenergic response and increased catecholamine levels • Less β-blocking effects and more vasodilation • Less sympathetic activation • Fewer adverse effects • More compliance • Most common side effects • HA • Dizziness • Orthostatic hypotension

  11. Nebivolol • Highest cardioselectivity of the β blockers • Vasodilates • Inhibits NADPH oxidase • decreased oxygen radical development • Produces lower peroxynitrite levels • Prevents endothelial cell NO synthesis (eNOS) • Increased levels of NO • Inhibits platelet aggregation • NO normally inhibits aggregation • Inhibits atherosclerosis • Inhibits edothelin-1 which normally promotes cell growth • Increased exercise tolerance compared to traditional β-blockers

  12. β-blocker Properties

  13. Summary • Third generation β-blockers are more effective at controlling HTN than traditional • More favorable metabolic effects • Better choice with multiple comorbid conditions • Safer in elderly and black populations • Fewer side effects • Older generation β-blockers are still useful for treatment of other cardiovascular diseases

  14. Citation • Fares, Hassan et al. Vasodilating Versus First-Generation β-blockers for Cardiovascular Protection. Postgraduate Medicine. Volume 124; Issue 2: 7-14. March, 2011.

More Related